Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2019 to Oct 2024
Affymetrix and NuGEN Collaborate to Advance Whole Transcript Analysis
- NuGEN Proprietary Whole Transcript Amplification System to Be Optimized for
Use With Affymetrix GeneChip(R) Brand Technology -
SANTA CLARA, Calif. and SAN CARLOS, Calif., Dec. 10 /PRNewswire-FirstCall/ --
Affymetrix, Inc., and NuGEN Technologies Inc., a privately held company
developing and commercializing products for high sensitivity nucleic acid
amplification and detection, announced today that they have entered into a joint
collaboration to develop NuGEN's Whole Transcript Amplification (WT-SPIA(TM))
system for use with Affymetrix GeneChip(R) brand technology. Financial terms
were not disclosed.
"We are delighted to work with Affymetrix towards our shared vision to integrate
NuGEN's novel amplification reagents with Affymetrix GeneChip technology," said
Jan D'Alvise, President and CEO of NuGEN. "We will develop WT-SPIA reagents for
the preparation of sample prior to hybridization to GeneChip arrays with the
goal of maintaining the accuracy, sensitivity, speed and simplicity that
characterizes NuGEN's commercially available Ovation Amplification System
products that are based upon the Ribo-SPIA(TM) technology. By collaborating
with Affymetrix, the industry leader for microarrays that enable whole genome
analysis, we plan to develop an integrated solution which will be instrumental
to advancing several important fields within genomic research."
"Following our collaborative research efforts, Affymetrix and NuGEN intend to
develop this promising new target amplification method to support the next
generation of GeneChip arrays from Affymetrix," said John E. Blume, Ph.D., Vice
President of Expression Research for Affymetrix. "Our collaborative efforts are
focused on providing the most powerful product solutions to drive the entire
field of whole genome analysis forward."
In this collaboration, NuGEN plans to develop amplification reagents that
replicate the entire length of mRNA transcripts and are optimized for use with
GeneChip technology. An important application of WT-SPIA will be the
identification of splice variants. Alternative mRNA splicing is an important
mechanism to expand the diversity of gene products because an estimated 60% of
human genes undergo alternative splicing of their coding units, or exons. This
process greatly increases the repertoire of proteins that are expressed in
different cell types at different stages of normal or pathological development.
Splice variants are believed to have significant functions in the control of
normal and disease states.
About Affymetrix
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve the quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip platform, to address growing markets
focused on understanding the relationship between genes and human health.
Additional information on Affymetrix can be found at http://www.affymetrix.com/
.
About NuGEN Technologies Inc.
NuGEN(TM) Technologies Inc., headquartered in San Carlos, CA, is a privately
held company focused on the development and commercialization of high
sensitivity amplification and detection systems for the analysis of nucleic
acids and proteins. NuGEN's mission is to develop amplification and detection
systems for genomic and proteomic research. The company's proprietary
technologies form the foundation for a wide range of methods and products used
by researchers to prepare samples for genetic analysis. NuGEN's initial
business focus is to apply its amplification and labeling technologies to gene
expression analysis.
NOTE: Affymetrix, the Affymetrix logo and GeneChip and are registered trademarks
owned or used by Affymetrix, Inc. NuGEN(TM), Ovation(TM), SPIA(TM),
Ribo-SPIA(TM) and WT-SPIA(TM) are trademarks or service marks of NuGEN(TM)
Technologies.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the Securities
Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including, but
not limited to risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches (including uncertainties
relating to its research collaboration with NuGEN), manufacturing, product
development, market acceptance, personnel retention, uncertainties related to
cost and pricing of Affymetrix products, dependence on collaborative partners,
uncertainties relating to sole source suppliers, uncertainties relating to FDA
and other regulatory approvals, competition, risks relating to intellectual
property of others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K for the year
ended December 31, 2002 and other SEC reports, including its Quarterly Reports
on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims
any obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in
Affymetrix' expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
This press release contains forward-looking statements that are subject to risks
and uncertainties, including continued growth in demand by researchers for total
RNA analysis, continued use of oligo and cDNA microarrays, acceptance by
researchers of the company's technologies and products, and competition from
existing and newly developed products. Accordingly, actual results may differ
materially from those anticipated. These forward-looking statements represent
the company's current expectations as of the date of this release. The company
disclaims, however, any intent or obligation to update these forward-looking
statements.
DATASOURCE: NuGEN Technologies Inc.; Affymetrix, Inc.
CONTACT: media, Anne Bowdidge, Director of Global Public Relations,
+1-408-731-5925, or investors, Doug Farrell, Vice President of Investor
Relations, +1-408-731-5285, both of Affymetrix; or Charlotte Rogers, V.P.,
Business Development of NuGEN, +1-650-590-3610; or media, Carin Canale or
Anette Breindl, Ph.D., +1-858-860-0266, both of Atkins + Associates for NuGEN
Web site: http://www.affymetrix.com/
Web site: http://www.nugentechnologies.com/